ExpreS2ion is streamlining its market communication with English as primary language

Report this content

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that the company has chosen to streamline its market communication, and will only provide press releases and interim reports in English. ExpreS2ion’s annual report will continue to be published in both Swedish and English. 

The decision to streamline the company’s market communication with English as the primary language was taken with consideration to the fact that ExpreS2ion is operating on a global market with customers, partners, and licensees in several regions including Europe, North America, Asia, and Australia. The resources previously allocated to translations will now be redirected to the investor relations section of the company’s website, which will be upgraded soon to become a better platform for communication with shareholders.

For additional information, please contact

ExpreS2ion Biotech Holding AB

Bent U. Frandsen, CEO      

Telephone: +45 4256 6869

E-mail: buf@expres2ionbio.com


Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telephone: +46 11-32 30 732

E-mail: ca@skmg.se

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatory validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.